Regeneron Pharmaceuticals reports $3.61 billion revenue for quarter ended March 31, 2026, up 19%

ยท REGN

Regeneron Pharmaceuticals reported revenue of $3.61 billion for the quarter ended March 31, 2026, an increase of 19% from the same quarter a year earlier ($3.03 billion).

For the same period it posted net income of $727.2 million, down 10.1%, or $6.75 per diluted share (7.27 a year earlier).

That is a net margin of 20.2%.

On Sanad's AAOIFI Standard 21 screen, Regeneron Pharmaceuticals is currently questionable: interest-bearing debt is 2.7% of market capitalisation (limit 30%), and impure income is 4.4% of revenue (limit 5%).

Source: 10-Q filed with the U.S. Securities and Exchange Commission on April 29, 2026. View the filing. Figures are as reported in the filing. This is information, not investment advice.

More Regeneron Pharmaceuticals news